Characteristics of Glucose Metabolism in Nordic and South Asian Subjects with Type 2 Diabetes

Cecilie Wium1,2,3*, Hanne Lovdal Gulseth1,2,3*, Erik Fink Eriksen1,3, Kåre Inge Birkeland1,3

1 Department of Endocrinology, Morbid Obesity and Preventive Medicine, Oslo University Hospital, Oslo, Norway, 2 Hormone Laboratory, Oslo University Hospital, Oslo, Norway, 3 Faculty of Medicine, University of Oslo, Oslo, Norway

Abstract

Background: Insulin resistance and type 2 diabetes are more prevalent in people of South Asian ethnicity than in people of Western European origin. To investigate the source of these differences, we compared insulin sensitivity, insulin secretion, glucose and lipid metabolism in South Asian and Nordic subjects with type 2 diabetes.

Methods: Forty-three Nordic and 19 South Asian subjects with type 2 diabetes were examined with intra-venous glucose tolerance test, euglycemic clamp including measurement of endogenous glucose production, indirect calorimetry measuring glucose and lipid oxidation, and dual x-ray absorptiometry measuring body composition.

Results: Despite younger mean ± SD age (49.7±9.4 vs 58.3±8.3 years, p = 0.001), subjects of South Asian ethnicity had the same diabetes duration (9.3±5.5 vs 9.6±7.0 years, p = 0.86), significantly higher median [inter-quartile range] HbA1c (8.5 [1.6] vs 7.3 [1.6] %, p = 0.024) and lower BMI (28.7±4.0 vs 33.2±4.7 kg/m², p < 0.001). The South Asian group exhibited significantly higher basal endogenous glucose production (19.1 [9.1] vs 14.4 [6.8] µmol/kgFFM-min, p = 0.003). There were no significant differences between the groups in total glucose disposal (39.1±20.4 vs 39.2±17.6 µmol/kgFFM-min, p = 0.99) or first phase insulin secretion (AUC0–8 min: 220 [302] vs 124 [275] pM, p = 0.35). In South Asian subjects there was a tendency towards positive correlations between endogenous glucose production and resting and clamp energy expenditure.

Conclusions: Subjects of South Asian ethnicity with type 2 diabetes, despite being younger and leaner, had higher basal endogenous glucose production, indicating higher hepatic insulin resistance, and a trend towards higher use of carbohydrates as fasting energy substrate compared to Nordic subjects. These findings may contribute to the understanding of the observed differences in prevalence of type 2 diabetes between the ethnic groups.

Introduction

The prevalence of type 2 diabetes (T2D) varies between different ethnic groups, and is known to be high in South Asians (SA) in their countries of origin, particularly in urban areas, but also after migration to Western countries [1]. Several theories as to why SA are especially prone to insulin resistance and T2D have been proposed. Among these, the adipose tissue overflow hypothesis proposes that SA have smaller superficial subcutaneous adipose tissue compartments for fat storage compared to Western Europeans. Hence, in situations of energy excess, fat is deposited in the more metabolically active deep subcutaneous and visceral adipose tissue compartments [2]. The metabolic inflexibility theory proposes that the normal switch in energy substrate between high lipid oxidation in the fasting state and high glucose oxidation in the post-prandial state is impaired in T2D. This results in accumulation of intramuscular lipids and increased plasma glucose values [3]. A third suggested mechanism involves the theory that SA have lower resting energy expenditure (REE) than Western Europeans, and therefore are more prone to obesity and insulin resistance. This theory is disputed, where some argue that the lower REE is due to differences in body composition and not ethnicity [4,5].

Although insulin resistance and T2D have been much studied in the SA population during recent years, few studies have used gold standard methods for the measurement of insulin resistance, and to our knowledge, no previous studies have reported endogenous glucose production (EGP) in SA T2D subjects.

In order to gain insights into possible explanations for the differences in prevalence of T2D between the two populations, we analysed baseline data from a vitamin D intervention trial in subjects with T2D and Nordic (NOR) or SA origin, all living in Oslo, Norway. Insulin sensitivity, glucose and fat oxidation, and insulin secretion was measured. The subjects all had serum levels of 25-hydroxyvitamin D ≤50 nM.
The primary aims of this study were to: 1) Explore possible differences in fasting and clamp hyperinsulinemic glucose metabolism, 2) Explore possible differences in insulin secretion, 3) Explore possible differences in energy expenditure, and 4) Assess possible associations between insulin sensitivity and secretion, and vitamin D status.

Methods

Ethics

All participants gave informed written consent prior to any study related procedure. The study was approved by the South-Eastern Norway Regional Committee for Medical and Health Research Ethics, and conformed to the Declaration of Helsinki.

Subjects

Sixty-two patients with T2D and 25-hydroxyvitamin D ≤50 nM, were recruited from our out-patient clinic, from general practice, from posters in the hospital lobby and in pharmacies, and from advertisements in local newspapers. Men and women with T2D, from the Oslo area in Norway, above 18 years of age, of Nordic or South Asian origin (born in a South Asian country and/or with both parents of South Asian origin) were eligible, regardless of type of anti-diabetic treatment. Full inclusion and exclusion criteria are displayed in Table 1. In total, 190 patients were screened. Sixty-two patients met with the inclusion criteria and were recruited, and 61 patients underwent initial intra-venous glucose tolerance tests (IVGTT) and clamp procedures. The Nordic group consisted of 40 Norwegians, 2 Danes and 1 Swede. The South Asian group consisted of 11 Pakistanis, 7 Sri Lankans (all Tamil) and 1 Indian. All but one of the South Asian participants were first generation immigrants. One Norwegian patient was excluded due to severe difficulties in getting intravenous access. Table 2 shows important characteristics of the two ethnic groups.

Anthropometrics

Height to the nearest 0.1 cm and weight to the nearest 0.1 kg were measured with participants wearing light clothing and no shoes. Waist circumference was assessed with a flexible tape measure with spring scale to ensure equal traction at every measurement, measuring at mid-point between the lowest rib margin and the iliac crest. The body surface area was calculated using Mostellers equation [6]. Fat mass (FM) in kg, percentage total body fat (%TBF), percentage truncal fat (% truncal fat) and fat free body mass (FFM) in kg were measured by dual x-ray absorptiometry (DXA) on a Lunar Prodigy from GE Healthcare.

IVGTT and Euglycemic Clamp

To enhance comparability of examinations, all patients were asked to stop oral antidiabetic drugs for two days, and insulin for at least 12 hours prior to examination. Patients were also asked to refrain from strenuous physical exercise and alcohol intake during these two days, and to arrive fasting for at least 10 hours, from the night before the examination.

A teflon catheter was placed in a vein at each elbow. All infusions were given in one vein, and all blood samples were drawn from the other vein, which was kept open by a slow infusion of NaCl,0.9%. The arm where blood samples were taken was kept at 37°C by a heating sleeve connected to a thermal control unit (Swerton AB, Vedelstad, Sweden), to arterialize blood samples.

We performed an IVGTT followed by a euglycemic, hyperinsulinemic clamp, with estimation of endogenous glucose production (EGP) using the stable isotope dilution method. A primed (170 mg) continuous (1.7 mg/min) infusion of [6,6-2H2] glucose (Cambridge Isotope Laboratories, Inc., Andover, MA) was maintained throughout the experiment. After a 2-h tracer equilibration period, the IVGTT was performed, with a <1-minute intravenous bolus injection of glucose 500 mg/mL, 0.3 g/kg body weight. Blood samples were drawn for plasma glucose concentration as well as serum insulin and C-peptide determinations at −2, 0, 2, 4, 6, 8, 10, 15 and 30 minutes after glucose bolus injection. Immediately following the IVGTT, a euglycemic, hyperinsulinemic clamp was performed using a modification of the method originally described by De Fronzo et al [7]. Human insulin (Actrapid®, Novo Nordisk, Bagsvaerd, Denmark) was diluted in 500 mL NaCl 0.9%, to 300 mU/mL, after having first added 2 mL of the patients own blood, to avoid insulin sticking to the walls of the bag, and 10 mmol KCl. Insulin was infused at a rate of 80 mU/m²min, after an initial bolus and 10 minute priming infusion, determined by the patients pre-clamp plasma glucose. The infusion was maintained for 2 ½ hours or more, until at least 30 minutes of stable euglycemia was obtained. When plasma glucose reached euglycemia, a variable infusion of glucose 200 mg/mL, enriched with 8 μg/g glucose of [6,6-2H2]-glucose was continually adjusted to maintain euglycemia.

Plasma glucose was regularly measured on a Precision Xceed glucometer (Abbott Laboratories, Abbott Park, IL), with five-minute intervals when the patient approached euglycemia. Control measurements at least every 30 minutes were performed on a Y.S.I 2300 STAT analyzer (Yellow Springs Instruments Inc, Yellow Springs, OH). At the end of the clamp, three measurements of serum insulin and fluoride/oxalate-plasma for analysis of [6,6-2H2]-glucose were taken at ten-minute intervals. The glucose infusion rate (GIR) in μmol/kg FFM-min was established.

IVGTT Calculations of Insulin Secretion

The Acute Insulin Response to glucose (AIRg) was calculated as the incremental area under the curve (AUC) for insulin from time 0–8 minutes and 0–30 minutes.

Endogenous Glucose Production Calculations

Calculations of endogenous glucose production (EGP) at the end of the basal equilibration period and during clamp euglycemia were performed. Both were steady state for plasma glucose, with only relatively small changes in glucose concentration and tracer enrichment over time. Thus, steady state equations, where rate of appearance equals rate of disappearance, have been applied for the calculation of both EGP and total glucose disposal (TGD) [8,9]. The EGP in the basal state was calculated as follows: EGPbasal = I[(Ei/Ep(basal)) – 1], where I is the rate of [6,6-2H2]-glucose infusion (μmol/m²min), Ei is the enrichment of the tracer infusion in moles percent excess (mpe) and Ep(basal) is the mean [6,6-2H2]-glucose enrichment in plasma (mpe) at the end of the basal stabilization period.

At the end of the euglycemic clamp, TGD was calculated as follows: TGD = [(1–Ei*GIR)Fmm/Epclamp]–1, where GIR is the exogenous glucose infusion rate (μmol/m²min), Fmm is the [6,6-2H2]-glucose enrichment (mpe) in the infused glucose, and Ep(clamp) is the mean [6,6-2H2]-glucose enrichment (mpe) in the plasma samples taken during the last 30 minutes of the clamp euglycemia. The EGP during clamp euglycemia, EGPclamp = TGD – GIR. Between subject and within subject coefficients of variation for plasma glucose levels in clamp steady state were 10.0% and 4.6% respectively.
### Table 1. Inclusion and exclusion criteria.

#### Inclusion criteria:
- Vitamin D deficiency defined as 25-hydroxyvitamin D < 50 nM
- Patients with type 2 diabetes (negative anti-GAD and anti-IA2), including drug naïve subjects, subjects using oral anti-diabetic medication and subjects on insulin treatment
- HbA1c < 11% (97 mmol/mol) at inclusion
- Men and women ≥ 18 years
- Nordic or South Asian ethnicity (from Pakistan, India, Bangladesh or Sri Lanka)
- Antihypertensive medication, lipid lowering drugs, oral contraceptives, hormone replacement therapy, multivitamin supplements and nutritional supplements are allowed

#### Exclusion criteria:
- Systolic Blood Pressure ≥ 160 mmHg or Diastolic Blood Pressure ≥ 90 mmHg at inclusion
- Significant renal disease or chronic renal impairment, GFR < 30 mL/min
- Significant liver disease or ASAT or ALAT ≥ 1.5 × upper limit of normal
- Malignancy during the last five years
- Hypercalcemia at inclusion or a history of kidney stone disease
- Pregnant or breastfeeding women
- Cardiovascular disease, defined as myocardial infarction, unstable angina pectoris or stroke, during the last 6 months prior to inclusion
- Anemia defined as hemoglobin below current reference limits
- BMI > 45 kg/m² or bariatric surgery performed during the last five years
- Drug or alcohol abuse
- Mental condition (psychiatric or organic cerebral disease) rendering the subject unable to understand the nature, scope and possible consequences of the study
- Any medical condition that in the judgment of the investigator would jeopardize the subject’s safety

Main inclusion and exclusion criteria. GAD: glutamic acid decarboxylase, IA2: protein tyrosine phosphatase, GFR: glomerular filtration rate, ASA T: aspartate aminotransferase, ALAT: alanine aminotransferase, BMI: body mass index.

doi:10.1371/journal.pone.0083983.t001

### Table 2. Description of patients.

|                  | NOR  | SA  | p     |
|------------------|------|-----|-------|
| Sex, males n (%) | 28 (65.1%) | 9 (47.4%) | 0.263  |
| Age, years       | 58.3 ± 8.3 | 49.7 ± 9.4 | **0.001**  |
| Age at diabetes debut, years | 48.7 ± 9.1 | 40.4 ± 10.4 | **0.002**  |
| Diabetes duration, years | 9.6 ± 7.0 | 9.3 ± 5.4 | 0.864  |
| Diabetes medication, n (%): | 0.554  |
| Lifestyle ± OAD or GLP-1 | 26 (60.5%) | 10 (52.6%) | 0.001  |
| Insulin ± OAD    | 17 (39.5%) | 9 (47.4%) | 0.034  |
| Diabetes complications, n (%): | 0.788  |
| Cardiovascular disease | 3 (7.0%) | 2 (10.5%) | 0.04  |
| Nephropathy/microalbuminuria | 8 (18.6%) | 2 (10.5%) | 0.22  |
| Other            | 17 (39.5%) | 7 (36.8%) | 0.87  |

Data are presented as number (percentage) or as mean ± standard deviation. p-values from *Student’s t*-test or a Chi square test. OAD: oral antidiabetic agent, GLP-1: Glucagon-like peptide 1 analogue. Microalb.: microalbuminuria. Other complications include ophthalmopathy, neuropathy, diabetic foot, sexual dysfunction and periodontal disease. NOR = Nordic, SA = South Asians.

doi:10.1371/journal.pone.0083983.t002

### Table 3. Anthropometrical and biochemical characteristics.

|                  | NOR n=43 | SA n=19 | p     |
|------------------|----------|---------|-------|
| Height, cm       | 173.6 ± 8.8 | 163.4 ± 8.4 | **<0.001**  |
| Weight, kg       | 100.4 [15.0] | 79.1 [15.0] | **<0.001**  |
| BMI, kg/m²       | 33.2 ± 4.7 | 28.7 ± 4.0 | **<0.001**  |
| Waist circumference, cm | 115.5 [18.0] | 100 [10.6] | **<0.001**  |
| Waist/Height ratio | 65.5 ± 7.2 | 61.2 ± 6.8 | **0.033**  |
| TBF, %           | 35.7 ± 7.2 | 34.5 ± 7.6 | 0.56  |
| Truncal fat, %   | 40.5 ± 5.7 | 40.1 ± 6.6 | 0.82  |
| FFM, kg          | 63.8 ± 9.7 | 50.1 ± 7.7 | **<0.001**  |
| FM, kg           | 33.1 [17.1] | 25.0 [10.8] | **<0.001**  |
| Fasting plasma glucose, mM | 9.1 [4.5] | 10.7 [6.4] | 0.08  |
| HbA1c, %         | 7.3 [1.6] | 8.5 [1.6] | **0.024**  |
| Fasting insulin, pM | 85.5 [99.0] | 68.0 [138.0] | 0.67  |
| Fasting C-peptide, pM | 1137 [785] | 1012 [431] | **0.049**  |
| 25(OH)vitamin D, nM | 40.1 [10.3] | 31.5 ± 14.0 | **0.009**  |

Data are presented as mean ± standard deviation or median [inter-quartile range]. NOR: Nordic, SA: South Asians, BMI: body mass index, TBF: total body fat, FFM: fat free mass, FM: fat mass, 25(OH)vitamin D: 25-hydroxyvitamin D. p-values are from Student’s t-test. *Student’s t*-test after Log-transformation.

doi:10.1371/journal.pone.0083983.t003
Indirect Calorimetry

Indirect calorimetry was performed in 38 of the 43 NOR and 14 of the 19 SA patients, using a Jaeger Oxycon Pro (Erich Jaeger, Viasys Healthcare, Germany) computerized flow-through canopy gas analyzer system. After a 10-minute adaptation period, expired and inspired air was continuously sampled and analyzed for O2 and CO2 content during a 30 minute steady state period at the end of the basal tracer equilibration period and at the end of the euglycemic clamp. Whole body substrate oxidation was estimated from the mean values of VO2 and VCO2 measured, and from measurement of urinary nitrogen (urea). Average basal and insulin stimulated glucose and lipid oxidation rates were calculated using Fryns’ equations [10]. Non-oxidative glucose metabolism was calculated as the difference between total body glucose disposal (as determined by the euglycemic clamp with tracer dilution method) and the rate of glucose oxidation (as determined by indirect calorimetry).

Blood Samples

Full blood glucose was measured by glucose oxidase method (YSI 2300, Yellow Springs, OH), and plasma glucose was calculated (full blood glucose x1.119). HbA1c was measured by HPLC on a Tosoh G7 analyser (Tosoh Corp., Tokyo, Japan), serum insulin and C-peptide were measured using an immuno-fluorometric assay (DELFIA) from Perkin Elmer Life Sciences (Wallac Oy, Turku, Finland). 25-hydroxyvitamin D was measured on a radioimmunoassay (RIA) kit from Diasorin (Stillwater, MN). [6,6-2H2]-glucose was measured by LC-MS/MS, via turbulent on a radioimmunoassay (RIA) kit from DiaSorin (Stillwater, MN). Serum insulin and C-peptide were measured using an immuno-fluorometric assay (DELFIA) from Perkin Elmer Life Sciences (Wallac Oy, Turku, Finland), 25-hydroxyvitamin D was measured on a radioimmunoassay (RIA) kit from Diasorin (Stillwater, MN). [6,6-2H2]-glucose was measured by LC-MS/MS, via turbulent flow chromatography (Cohesive technologies RXT1, Franklin, MA) combined with tandem mass spectrometry (Sciex AP13000, Applied Biosystems, Foster City, CA) as previously described [11], at the Clinical Metabolomics Core Facility, (Rigshospitalet, Copenhagen, Denmark). Urinary urea was measured by enzymatic-kinetic UV assay on a Roche Modular P analyser.

Statistical Analysis

Data are presented as mean ± standard deviation or median [inter-quartile range] unless otherwise specified. We analyzed non-normally distributed data log-transformed, or using non-parametric methods, as appropriate. Student’s t tests or Mann Whitney U tests were used for comparison of continuous variables between groups, and paired samples t-tests were used for within groups analysis of change. For comparison of categorical data between patient groups, the Chi square test for independence was used. Spearman’s correlation coefficients (r) were used. One-way between-groups ANCOVA was performed, with preliminary checks to ensure no violation of the assumptions of normality, linearity, homogeneity of variances and homogeneity of regression slopes. Multiple linear regression analyses were performed, with log-transformation of parameters when needed, to ensure no violation of the assumptions of normality, linearity and homoscedasticity. In regression analyses NOR = 1 and SA = 2. A two-sided p-value <0.05 was deemed significant, and uncorrected p-values are presented. Bonferroni-Holm corrections were performed, showing that p-values <0.01 remained <0.05 after correction. Statistical analyses were performed with SPSS 19.0 for windows (SPSS Inc., Chicago, IL).

Results

General Description

Anthropometric and biochemical characteristics by ethnic group are presented in Table 3. The SA subjects were significantly shorter and leaner than the NOR subjects, but had a higher median HbA1c, whereas median fasting C-peptide was significantly higher in the NOR group. Despite a higher waist circumference and waist-to-height ratio in the NOR subjects, the SA still had similar percentage total and truncal fat to the NOR group. Adjusting for sex and/or age did not change these results (data not shown).

Endogenous Glucose Production

EGPbasal was significantly higher in the SA than the NOR group, as shown in Table 4 and Figure 1A. This difference remained significant after adjustment for possible confounders, including sex, age, height, weight, BMI, %TBF, FFM, HbA1c, fasting C-peptide, or fasting plasma glucose (data not shown). During clamp hyperinsulinemia the EGP was reduced, the ethnic difference in endogenous glucose production (EGPclamp) was attenuated, and no longer significant. EGPclamp was detectable in all patients, ranging from 3.4% to 90.6% of the total glucose disposal rate (TGD), with a median of 25.8%. In an effort to find predictors of EGPclamp variation, we performed simple correlations between EGPclamp and parameters which could influence EGPclamp. The following parameters correlated with EGPclamp with a p-value <0.1; diabetes duration, fasting plasma glucose (FPG), se-insulin at end of clamp, fasting se-C-peptide and HbA1c (Table 5). We then performed an all subsets multiple regression analysis, using logEGPclamp as dependent variable. Log FPG was the only significant parameter to remain, with an unstandardized beta = 0.78, p = 0.002 and an R² of only 0.13. The separate correlation coefficients in the ethnic subgroups showed differences: FPG and most of the other parameters correlated significantly to EGPclamp only in the NOR group. The correlation between GIR and EGPclamp was neither significant in the total patient group nor in the two separate ethnic subgroups. The correlation between TGD and EGPclamp was significant in the SA subgroup but not the NOR subgroup.

Table 4. Endogenous glucose production, insulin sensitivity and insulin secretion.

|                | NOR n=41 | SA n=18 | p    |
|----------------|----------|---------|------|
| EGPbasal μmol/kg FFM-min | 14.4 [6.8] | 19.1 [9.1] | 0.003 |
| EGPclamp μmol/kg FFM-min | 8.9 [6.7] | 10.8 [10.4] | 0.216 |
| EGPclamp % of TGD | 24.9 [24.3] | 38.7 [27.7] | 0.107 |
| GIR μmol/kg FFM-min | 28.9 ± 15.8 | 24.7 ± 14.6 | 0.343 |
| TGD μmol/kg FFM-min | 39.2 ± 17.6 | 39.1 ± 20.4 | 0.990 |
| Se-insulinclamp clamp pM | 1290 [425] | 1270 [1087] | 0.889 |
| AIRg 0–8 min AUC 0–8 min | 124 [275] | 220 [302] | 0.352 |
| AIRg 0–30 min AUC 0–30 min | 1003 [1505] | 852 [1452] | 0.383 |
| LogAIRg 0–8 min LogAUC 0–8 min | 2.15 ± 0.52 | 2.34 ± 0.44 | 0.201 |
| LogAIRg 0–30 min LogAUC 0–30 min | 3.06 ± 0.36 | 2.98 ± 0.32 | 0.425 |

Data are presented as mean ± standard deviation or median [inter-quartile range]. p-values from Student’s t-tests or Mann-Whitney U tests as appropriate. NOR: Nordic, SA: South Asians, EGP: endogenous glucose production, FFM: fat free mass, TGD: total glucose disposal, GIR: glucose infusion rate, AIRg: acute insulin response to glucose, AUC: area under the curve (from 0–8 minutes and 0–30 minutes of the intra-venous glucose tolerance test). For LogAIRg 0–8 min n = 36 NOR and 16 SA, and for LogAIRg 0–30 min n = 40 NOR and 17 SA. doi:10.1371/journal.pone.0083983.t004
A) Total systemic glucose delivery per kg FFM during basal and clamp conditions

- Basal NOR: $p = 0.003$
- Basal SA
- Clamp NOR: $p = 0.35$
- Clamp SA: $p = 0.22$

B) Mean (SEM) Insulin during IVGTT

- NOR
- SA
Figure 1. Glucose delivery and insulin secretion during basal and clamp conditions. A) Median [inter-quartile range] values of basal and clamp glucose delivery per kg fat free mass (FFM), both from endogenous glucose production and exogenous glucose infusion. p-values from Mann-Whitney U tests. B) Mean (standard error of mean) serum insulin levels during the 30-minute intra-venous glucose tolerance test. NOR = Nordic, SA = South Asians.

doi:10.1371/journal.pone.0083983.g001

**Insulin Sensitivity**

There was no significant ethnic difference in insulin sensitivity expressed as the TGD in μmol/kgFFM·min (Table 4, Figure 1A). After adjusting TGD for log EGPclamp (beta = 28.4, p = 0.001) and log waist circumference (beta = −114.7, p = 0.028), in a multiple regression analysis, ethnicity came closer to significance (beta = −9.1, p = 0.111). Further adjusting for age (p = 0.84) or sex (p = 0.97) was not significant.

**Insulin Secretion**

All but seven of the 60 subjects where an IVGTT was performed had some preserved first phase insulin secretion, (increased incremental AUC0–8). and two thirds of the patients displayed an AUC0–8>100 μM. Insulin secretion (AIRg) did not differ significantly between the two ethnicities (Table 4, Figure 1B). After adjusting for HbA1c in a multiple regression analysis, ethnicity came closer to significance (beta = −3.2, p = 0.052), with adjusted mean (SEM) values of 7155 (121) kJ/day in NOR and 6954 (239) kJ/day in SA patients. REE correlated highly with basal fat oxidation (r2 = 0.48, p = 0.002 in NOR and 0.64, p = 0.014 in SA patients), but not with basal glucose oxidation (r2 = −0.06, p = 0.73, and −0.10, p = 0.75, respectively), or non-oxidative glucose metabolism (r2 = −0.16, p = 0.36, and r2 = 0.40, p = 0.16 respectively), although SAs showed a stronger correlation between REE and non-oxidative glucose metabolism than the NOR group.

**Table 5. Correlations to endogenous glucose production during clamp.**

| Total patients | NOR | SA |
|----------------|-----|----|
|                | n = 57 | n = 39 | n = 18 |
| Diabetes duration | r2 | 0.251 | 0.343 | −0.058 |
|                  | p   | 0.059 | 0.033 | 0.819 |
| Fasting plasma glucose | r2 | 0.420 | 0.524 | 0.057 |
|                  | p   | 0.001 | 0.001 | 0.823 |
| Serum insulin at end of clamp | r2 | −0.295 | −0.187 | −0.387 |
|                  | p   | 0.026 | 0.254 | 0.113 |
| Fasting serum C-peptide | r2 | −0.272 | −0.320 | −0.034 |
|                  | p   | 0.040 | 0.047 | 0.926 |
| HbA1c | r2 | 0.335 | 0.338 | 0.101 |
|                  | p   | 0.011 | 0.035 | 0.689 |
| Exogenous glucose infusion rate | r2 | −0.035 | −0.116 | 0.228 |
|                  | p   | 0.798 | 0.480 | 0.363 |
| Total glucose disposal | r2 | 0.318 | 0.156 | 0.591 |
|                  | p   | 0.016 | 0.342 | 0.010 |

Table 5. Correlations to endogenous glucose production during clamp.

Data are presented as Spearman’s correlation coefficients (r2) with corresponding p-values. Significant correlations in bold. NOR: Nordic, SA: South Asians.

doi:10.1371/journal.pone.0083983.t005

**Glucose and Fat Oxidation and Non-oxidative Glucose Metabolism**

Figure 2 displays glucose and fat metabolism in peripheral tissues in the basal fasting and the hyperinsulinemic clamp state, measured by indirect calorimetry. Figure 2A demonstrates that higher endogenous glucose production in SA leads to increases in both oxidative and non-oxidative metabolism in peripheral tissues. This figure also demonstrates the higher oxidative metabolism in the basal state in both ethnic groups, and that non-oxidative glucose metabolism increases more than oxidative in the clamp hyperinsulinemic state in both ethnicities.

Basal fat oxidation measured per kg fat free body mass was similar in the two ethnic groups (Table 6, Figure 2B). Fat oxidation decreased during clamp hyperinsulinemia, as glucose metabolism increased. These changes were similar in the two groups.

**Discussion**

In this study we examined ethnic differences in glucose and fat metabolism and energy expenditure in basal and clamp hyperinsulinemic conditions in subjects with T2D, of SA or NOR ethnicity, living in Oslo, Norway. We found evidence of ethnic differences in fasting endogenous glucose production, and
A) Oxidative and non-oxidative glucose metabolism

![Graph showing oxidative and non-oxidative glucose metabolism](image)

- NOGM: p=0.009
- OGM: p=0.008
- NOGM: p<0.001
- OGM: p<0.001
- p=0.88
- p=0.003
- p=0.17
- p=0.15
- p=0.90
- p=0.33

B) Mean (SEM) fat oxidation in Nordic and South Asian patients

![Graph showing mean (SEM) fat oxidation](image)

- p<0.001
- p=0.005
- p=0.57
- p=0.56
indicators of possible differences in the choice of substrates for energy expenditure both in basal and clamp conditions.

The concept of ethnicity and ethnic groups is complex, consisting of both socio-cultural and biological components that are not clearly defined [12]. The term South Asian ethnicity is often used, although the South Asian region is diverse, with several countries (Pakistan, India, Bangladesh and Sri Lanka), and differences in culture, religion and diet. In diabetes research, using the term South Asian can nonetheless be justified, in view of the fact that the high prevalence of diabetes and increased insulin resistance is present in the whole region [13], particularly in urban areas, and also after migration to Western countries [1].

This study shows a significantly higher fasting EGP in SA compared to NOR patients, which was not explained by any of the examined possible confounding factors. During clamp hyperinsulinemia the EGP was lowered, and the ethnic difference was attenuated. Even so, EGP_{clamp} was still not negligible, and constituted almost 40% of TGD in SA and 25% in NOR patients. Hyperinsulinemia during clamp is often said to suppress EGP almost entirely [14,15], and euglycemic clamp studies are still frequently performed without the measurement of endogenous glucose production [16,17]. However, several authors have demonstrated that EGP_{clamp} persists [18–20]. We here present further evidence that EGP_{clamp} can be substantial in type 2 diabetic patients, even with serum insulin concentrations during clamp as high as 1000–1500 pM. This finding underscores the importance of controlling for hepatic glucose production during clamp studies.

Measuring EGP via the isotope tracer dilution method is both time consuming and costly. In an attempt to find predictors for the estimation of EGP_{clamp} from variables that are easier to measure, we looked at a group of variables which correlated with EGP_{clamp}. Only FPG remained significantly related to EGP_{clamp} in regression analyses, and it explained only 15% of EGP_{clamp} variation in the whole patient group. When looking at the correlations in the separate ethnic subgroups, most variables only correlated significantly in the NOR group. The exogenous glucose infusion rate did not correlate to EGP_{clamp} at all. In the SA group, the only significant correlation was between EGP_{clamp} and TGD, merely reflecting the high percentage of EGP_{clamp} in TGD in this group. We therefore suggest that measuring EGP_{clamp}, in addition to the exogenous glucose infusion rate, is essential for correct estimation of total glucose disposal rate.

Some ethnic groups residing in tropical climates, including SA, have previously been shown to have lower REE than Westerners [21], however, several authors have advocated the need for adjusting REE for fat free mass (FFM) and fat mass (FM), as well as age and sex [4,22]. The lower REE in SA is in this way shown to be due to differences in body composition and not due to ethnicity per se. We find it to be the case also in our study. Our two ethnic groups display clear differences in body composition, and adjusting for these differences, mainly FFM, attenuates the ethnic difference seen in REE. This, however, brings us back to the complex concept and definition of ethnicity, whence it can also be argued that lower FFM is an ethnic characteristic of South Asians. This has been described in other studies [23,24].

In basal, resting conditions, energy production is for the most part derived from lipids, and less from carbohydrates [25]. This is also reflected in our study, by the highly significant correlation between REE and fat oxidation in both ethnicities. In the SA subgroup, however, there is also a near-significant correlation between REE and EGP_{basal}. This could signify increased use of carbohydrates as energy substrate in the fasting state in SA, to such an extent that it becomes important for the total REE. However, we did not find any ethnic differences in basal RQ or in ∆RQ from fasting to clamp hyperinsulinenic conditions, that would have clearly indicated an ethnic difference.

### Table 6. Basal and Clamp Indirect Calorimetry.

|                     | NOR            | SA            | p    |
|---------------------|----------------|---------------|------|
| Basin glucose oxidation | µmol/kg FFM-min | 6.5±4.5       | 8.5±4.0   | 0.151 |
| Basal non-oxidative glucose consumption | µmol/kg FFM-min | 9.0±5.9       | 12.0±9.1  | 0.167 |
| Basal fat oxidation | mg/kgFFM-min   | 1.2±0.37      | 1.18±0.36 | 0.572 |
| Clamp glucose oxidation | µmol/kg FFM-min | 12.7±4.6     | 14.2±6.7  | 0.331 |
| Clamp non-oxidative glucose consumption | µmol/kg FFM-min | 26.3 [17.6]  | 26.6 [29.5]  | 0.697 |
| Clamp fat oxidation | mg/kgFFM-min   | 0.89±0.38     | 0.81±0.50 | 0.557 |
| REE                 | kl/day         | 7465±1202     | 6104±1214 | 0.001 |
| EE_{clamp}          | kl/day         | 7750±1315     | 6263±1139 | <0.001 |
| RQ_{basal}          | 0.79±0.05      | 0.80±0.04     | 0.207 |
| RQ_{clamp}          | 0.84±0.05      | 0.86±0.06     | 0.440 |
| ∆RQ                 | 0.052±0.035    | 0.053±0.062   | 0.994 |

Data are presented as mean ± standard deviation or median (inter-quartile range). p-values from Student’s t-tests or Mann-Whitney U tests as appropriate. NOR: Nordic, SA: South Asians, FFM: fat free mass, REE: resting energy expenditure, EE_{clamp}: energy expenditure during clamp, RQ: respiratory quotient, ∆RQ: change in respiratory quotient from basal to clamp conditions.

doi:10.1371/journal.pone.0083983.t006
difference in metabolic flexibility. The values of basal RQ and ΔRQ in our subjects were comparable to the group with diabetes in the recently published study by van de Weijer [26]. In that study, they also demonstrated that insulin stimulated RQ is mainly dependent on glucose disposal rates, which in our study are similar in the two groups.

Our NOR participants are significantly more obese than the SA, which could in part explain why there is no obvious ethnic difference in TGD. After adjustment for difference in waist circumference, as well as the endogenous glucose production, the ethnic difference in TGD came closer to significance.

In our study we found a non-significant trend towards higher both oxidative and non-oxidative glucose metabolism in SA compared to NOR subjects in the basal, post-absorptive state. The total EGPbasal was significantly higher. This points towards a higher degree of hepatic insulin resistance in SA. One could speculate that a possible higher basal oxidative glucose metabolism in muscle, triggered by increased substrate availability from fasting hyperglycemia, leads to less use of lipids as energy substrate, again leading to lipid accumulation and further aggravation of the hepatic insulin resistance, as described in the metabolic inflexibility hypothesis [3]. In post-absorptive conditions skeletal muscle contribution to total metabolism is modest [3]. A possible ethnic difference in muscle metabolism could thus have been masked.

The hepatic insulin resistance could also initially have been caused by increased lipid storage in the liver due to adipose tissue overflow [2]. Percentage truncal fat was similar in our two ethnic groups, although the NOR group was significantly more obese. In a previous study we found that even though a group of Pakistani and Norwegian subjects with T2D had similar abdominal adipose tissue distribution, the visceral adipose tissue was more metabolically active in the Pakistani subjects (Wium C, Eggesbo HB, Ueland T et al, 2013, unpublished data). An increased supply of NEFA from visceral adipose tissue to the liver would, in addition to the effect of increasing the insulin resistance, constitute a source of substrate for gluconeogenesis.

Gluconeogenesis is known to be increased in subjects with T2D, being in large part responsible for the increased post-absorptive EGP. When using [6,6-2H2] glucose as tracer, Cori cycling is included in the estimation of the total glucose disposal, and has been shown to be increased 25% in T2D in general [27]. It is possible that the increase in non-oxidative glucose metabolism in SA in large part corresponds to increased Cori cycling, due to substrate availability through hyperglycemia in tissues, with lactic acid production in muscle or other tissues by anaerobic glycolysis, then transport back to the liver and re-use as substrate in gluconeogenesis, creating a vicious circle.

The data in this study are baseline results from a vitamin D intervention trial. It was therefore of interest to look for associations between baseline 25-hydroxyvitamin D levels and measures of insulin sensitivity and insulin secretion. We found significantly lower median 25-hydroxyvitamin D levels in the SA group. Could differences in vitamin D status explain some of the ethnic differences in glucose metabolism? Several epidemiological studies have in recent years shown a relationship between vitamin D and diabetes [28,29], the metabolic syndrome [29], insulin resistance [30,31], and some studies also with insulin secretion [32]. However, in most of the published studies that report significant associations, or an effect of vitamin D intervention, the primary end points have been surrogate markers based on fasting blood values, like the HOMA indices [28,33,34]. The few studies using more sophisticated methods, like OGGT, IVGTT or clamps have usually not been able to show similar significant relationships [35–39]. We did not find any association between levels of 25-hydroxyvitamin D and TGD or AIRg. The question therefore still remains whether there is a genuine and causal relationship between vitamin D and diabetes, and we have to await results from randomised, controlled trials.

A strength of this study was the use of gold standard methods such as the euglycemic clamp with tracer dilution, coupled with indirect calorimetry. This enabled us to measure both fasting endogenous glucose production and insulin sensitivity, as well as carbohydrate and fat metabolism, both in the basal and hyperinsulinemic state. To our knowledge, this has not been reported in SA subjects with T2D previously. The patients were included by a large variety of approaches, with wide inclusion criteria, the main restriction being the 25-hydroxyvitamin D levels ≤50 nM, with the aim of securing broad representativeness. The following limitations must be noted: The data presented here are cross-sectional. No efforts towards matching of the two ethnic groups at baseline were made. The inclusion of SA patients in the study proved challenging, hence the SA group was limited in size, increasing the risk of Type II statistical errors. Further studies in a larger group of patients, will therefore be necessary to confirm some of the findings that are still uncertain in our study. We selected only subjects with low levels of vitamin D, and our results therefore cannot be generalized to the whole population of subjects with T2D, although low vitamin D levels are common in T2D. Nevertheless, we did not find any correlation between 25-hydroxyvitamin D levels and insulin sensitivity or insulin secretion.

This is an exploratory study, and we have judged it appropriate not to show p-values corrected for multiple testing. Bonferroni-Holm corrections were performed, showing that p-values <0.01 remained significant. However, due to the high risk of missing a genuine difference that is clinically significant, we still focus on the non-corrected tests [40]. Hence, there is also a risk of reporting p-values <0.05 by chance.

Conclusions

We have demonstrated higher basal EGP in SA patients with established T2D. Clamp EGP can be substantial in patients with established T2D, and cannot be estimated from the surrogate markers measured. We found no ethnic difference in insulin sensitivity or in first phase insulin secretion. Findings of near significant correlations between REE, EEclamp and EGP in the SA group only, might indicate increased post-absorptive glucose metabolism in the SA group, at the expense of lipid metabolism, but these results have to be confirmed in larger studies. Finally, we found no indication of any relation between vitamin D and insulin sensitivity and secretion.

Acknowledgments

We thank Professor Gerrit Van Hall at the Clinical Metabolomics Core Facility, Rigshospitalet, Copenhagen, Denmark, who performed the deuterated glucose tracer analyses, and graciously shared his knowledge in tracer analysis and calculations. We also thank the Simon Fouger Hartmann Foundation for providing financial support to the YSI glucose analyser, and Abbott Laboratories, Norway, for providing strips for the Precision Xceed glucometer used during the euglycemic clamp.

Author Contributions

Conceived and designed the experiments: CW HLG EFE KIB. Performed the experiments: CW HLG. Analyzed the data: CW HLG KIB. Wrote the paper: CW HLG. Critical revision of manuscript: CW HLG EFE KIB. Final approval of manuscript: CW HLG EFE KIB.
References

1. Gujral UP, Pradeepa R, Weber MB, Narayan KM, Mohan V (2013) Type 2 diabetes in South Asians: similarities and differences with white Caucasian and other populations. Ann N Y Acad Sci 1281: 51–63.

2. Saurer MA, Ajduk, Bhojraj P, Prabhakaran D, Narrafsheghan N, Tchernof A (2007) Why might South Asians be so susceptible to central obesity and its atherogenic consequences? The adipose tissue overflow hypothesis. Int J Epidemiol 36: 220–225.

3. Kelley DE, Mandarino LJ (2000) Fuel selection in human skeletal muscle in insulin resistance: a reexamination. Diabetes 49: 677–683.

4. Soares MJ, Pieris LS, O'Dea K, Shetty PS (1998) No evidence for an ethnic influence on basal metabolism: an examination of data from India and Australia. Br J Nutr 79: 333–341.

5. Shetty P (2005) Energy requirements of adults. Public Health Nutr 8: 994–1009.

6. Mosteller RD (1987) Simplified calculation of body-surface area. N Engl J Med 317: 1098. 10.1056/NEJM198702231171177 [doi].

7. DeFronzo RA, Tobin JD, Andres R (1979) Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol 237: E214–E223.

8. Radzisz J, Pye S (2002) Quantitation of basal endogenous glucose production in Type II diabetes: importance of the volume of distribution. Diabetologia 45: 1053–1054.

9. Vella A, Rizza RA (2009) Application of isotopic techniques using constant specific activity or enrichment to the study of carbohydrate metabolism. Diabetes 58: 2108–2174.

10. Frayn KN (1983) Calculation of substrate oxidation rates in vivo from gas-exchange. J Appl Physiol 55: 628–634.

11. Wolk E, Myint H, Groudhall TS, Pedersen BK, van HG (2011) The role of leptin in human lipid and glucose metabolism: the effects of acute recombinant human leptin infusion in young healthy males. Am J Clin Nutr 94: 1533–1544.

12. Anand SS (1999) Using ethnicity as a classification variable in health research: perpetuating the myth of biological determinism, serving socio-political agendas, or making valuable contributions to medical sciences? Ethn Health 4: 241–244.

13. Jayawardena R, Kanasinghe P, Byrne NM, Soares MJ, Catulanda P et al. (2012) Prevalence and trends of the diabetes epidemic in South Asia: a systematic review and meta-analysis. BMC Public Health 12: 380.

14. DeFronzo R, Deibert D, Heimler R, Felig P, Soman V (1979) Insulin sensitivity and insulin binding to monocytes in maturity-onset diabetes. J Clin Invest 63: 939–946.

15. Reaven GM, Moore J, Greenfield M (1983) Quantification of insulin secretion and in vivo insulin action in nonobese and moderately obese individuals with normal glucose tolerance. Diabetes 32: 600–604.

16. Nair KS, Bigelow ML, Asmann YW, Chow LS, Coenen-Schimke JM et al. (2003) Simplified calculation of body-surface area. N Engl J Med 317: 1098. 10.1056/NEJM198702231171177 [doi].

17. Chandalia M, Lin P, Seenivasan T, Livingston EH, Snell PG et al. (2007) Insulin resistance and type 2 diabetes: association with insulin resistance and beta-cell dysfunction in subjects at risk for type 2 diabetes. Diabetes 56: 565–573.

18. Nair KS, Bigelow ML, Asmann YW, Chow LS, Coenen-Schimke JM et al. (2008) Comparison of body-surface area and lean body mass, age, and circulating thyroxine but not sex, circulating leptin, or triiodothyronine. Am J Clin Nutr 82: 941–948.

19. Lear SA, Kohli S, Bandy GP, Tchernev A, Sniderman AD (2009) Ethnic variation in fat and lean body mass and the association with insulin resistance. J Clin Endocrinol Metab 94: 4969–4972.

20. Stafield KM, Wells JC, Fewtrell MS, Frost C, Leon DA (2012) Differences in body composition between infants of South Asian and European ancestry: the London Mother and Baby Study. Int J Epidemiol 41: 1409–1418.

21. Johnstone AM, Mutch SG, Duncan JS, Rance KA, Spradlin JR (2005) Factors influencing variation in basal metabolic rate include fat-free mass, fat mass, age, and circulating thyroxine but not sex, circulating leptin, or triiodothyronine. Am J Clin Nutr 82: 941–948.

22. Ghanasia E, Brun JF, Mercier J, Raymond E (2007) Oxidative mechanisms at rest and during exercise. Clin Chim Acta 383: 1–20.

23. van de Weijer T, Sparks LM, Phielix E, Meex RG, van Herpen NA et al. (2013) Relationships between mitochondrial function and metabolic flexibility in type 2 diabetes mellitus. PLoS One 8: e51648.

24. Tappy L, Pasquet N, Touman P, Schneider P, Jéquier E (1995) Assessment of glucose metabolism in humans with the simultaneous use of indirect calorimetry and tracer techniques. Clin Physiol 15: 1–12.

25. Khan H, Kumutsor S, Franco OH, Chowdhury R (2013) Vitamin D, type 2 diabetes and other metabolic outcomes: a systematic review and meta-analysis of prospective studies. Proc Nutr Soc 72: 89–97.

26. Pittas AG, Nelson J, Mitri J, Hillmann W, Garganta C et al. (2012) Plasma 25-hydroxyvitamin D and progression to diabetes in patients at risk for diabetes: an ancillary analysis in the Diabetes Prevention Program. Diabetes Care 35: 565–573.

27. Scragg R, Sowers M, Bell C (2004) Serum 25-hydroxyvitamin D, diabetes, and ethnicity in the Third National Health and Nutrition Examination Survey. Diabetes Care 27: 2013–2018.

28. Lu L, Yu Z, Pan A, Hu FB, Franco OH et al. (2009) Plasma 25-hydroxyvitamin D concentration and metabolic syndrome among middle-aged and elderly Chinese individuals. Diabetes Care 32: 1278–1283.

29. Kayanil P, Viehr R, Renakaran R, Knight JA, Qj Y et al. (2010) Association of vitamin D with insulin resistance and beta-cell dysfunction in subjects at risk for type 2 diabetes. Diabetes Care 33: 1379–1381.

30. von Hurst PR, Stonehouse W, Coad J (2010) Vitamin D supplementation reduces insulin resistance in South Asian women living in New Zealand who are insulin resistant and vitamin D deficient - a randomised, placebo-controlled trial. Br J Nutr 103: 549–555.

31. Belenchia AM, Tosh AK, Hillman LS, Peterson CA (2013) Correcting vitamin D insufficiency improves insulin sensitivity in obese adolescents: a randomized controlled trial. Ann J Clin Nutr 97: 774–781.

32. Gulich HL, Gjelstad IM, Tierney AG, Lovegrove JA, DeFoor C et al. (2010) Serum vitamin D concentration does not predict insulin action or secretion in European subjects with the metabolic syndrome. Diabetes Care 33: 923–925.

33. Grannnes G, Fjørresau Y, Almas B, Jorde R (2011) Vitamin D, insulin secretion, sensitivity, and lipids: results from a case-control study and a randomized controlled trial using hyperglycemic clamp technique. Diabetes 60: 2748–2757.

34. Harris SS, Pittas AG, Palermo NJ (2012) A randomized, placebo-controlled trial of vitamin D supplementation to improve glycaemia in overweight and obese African Americans. Diabetes Obes Metab 14: 789–794.

35. Davidson MB, Duran P, Lee ML, Friedman TC (2013) High-dose vitamin D supplementation in people with prediabetes and hypovitaminosis D. Diabetes Care 36: 260–266.

36. Hoseini SA, Aminorroaya A, Iraj B, Amini M (2013) The effects of oral vitamin D supplement on the insulin resistance index and insulin secretion in South Asian women living in New Zealand who are insulin resistant and vitamin D deficient - a randomised, placebo-controlled trial. Br J Nutr 103: 549–555.

37. Harris SS, Pittas AG, Palermo NJ (2012) A randomized, placebo-controlled trial of vitamin D supplementation to improve glycaemia in overweight and obese African Americans. Diabetes Obes Metab 14: 789–794.

38. Davidson MB, Duran P, Lee ML, Friedman TC (2013) High-dose vitamin D supplementation in people with prediabetes and hypovitaminosis D. Diabetes Care 36: 260–266.

39. Hoseini SA, Aminorroaya A, Iraj B, Amini M (2013) The effects of oral vitamin D on insulin resistance in pre-diabetic patients. J Res Med Sci 18: 47–51.

40. Rothman KJ (1990) No adjustments are needed for multiple comparisons. Epidemiology 1: 43–46.